Clinical trial / 2002
Daily antioxidant vitamin supplementation for 5 years did not reduce vascular events, cancer incidence, or mortality in high-risk UK adults.
A total of 20,536 high-risk UK adults were randomly allocated to receive daily antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene) or placebo for 5 years. There were no significant differences in all-cause mortality (14.1% vitamin vs 13.5% placebo), vascular deaths (8.6% vs 8.2%), or non-vascular deaths (5.5% vs 5.3%). Major vascular events occurred in 22.5% of participants in both the vitamin and placebo groups (event rate ratio 1.00, 95% CI 0.94-1.06). There were also no significant effects observed on cancer incidence or hospitalisation for other non-vascular causes.
- Study type
- Randomized placebo-controlled trial
- Who was studied
- 20,536 UK adults aged 40-80 with coronary disease, other occlusive arterial disease, or diabetes
- What was measured
- All-cause mortality, major coronary events, fatal or non-fatal vascular events, cancer incidence, and other major morbidity
THE PAPER
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group. Lancet, 2002.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.